About Half of Celgene Subjects with Peripheral T-Cell Lymphoma Achieve Complete Response

Celgene Corporation’s study results of romidepsin (Istodax) in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of patients with peripheral T-cell lymphoma (PTCL) showed 51% of patients achieved a complete response, according to a Celgene press release.

Thirty-seven patients took Istodax at varying dosages, plus CHOP, according to Celgene. Two patients were excluded from the efficacy analysis after they experienced myocardial infarction, and a third individual took only CHOP after experiencing acute cardiac failure.

Of the remaining patients, 51% achieved a complete response, 17% achieved a partial response, and 26% saw progressive disease.

Internal server error